Subject: Biosyn
Date: Published: 1/31/92 (43 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    A Final Visit With Three Start-Up
    Companies Finds Them Still Hopeful
    ----
    By Brent Bowers
    Staff Reporter of The Wall Street Journal


[16 lines irrelevant to AIDS removed.  -- sysop]

    The president of Biosyn Inc., a Philadelphia developer of
 products to prevent the spread of AIDS, says several
 long-delayed marketing and licensing agreements are about to
 be signed and exults that the Food and Drug Administration is
 showing unexpected receptiveness to its proposals for
 clinical testing.  Six months pregnant, she says she aims to
 "go into labor in the office."
    The New Jersey marketing manager who started Bottle
 Toppers in her home to make designer outfits for wine bottles
 says her two new partners have breathed life into the
 enterprise -- but sales are still disappointing.  Even if her
 business fails, she says, she'll come out ahead because of
 the knowledge gained.

[31 lines irrelevant to AIDS removed.  -- sysop]

    Meantime, Biosyn is switching directions, putting on hold
 a disinfectant that it once touted because of regulatory
 demands by the Environmental Protection Agency.  By contrast,
 it says it is making unforeseen progress in developing its
 virus-killing spermicide, its treatment for oral yeast
 infections in AIDS patients and its barrier cream for latex
 gloves.  Dr. Malamud says Biosyn's relationship with the FDA
 is proceeding "much more smoothly than we anticipated," and
 he says FDA approval for human studies on one or more
 products is certain this year.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]